Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Peter N. Fonjungo is active.

Publication


Featured researches published by Peter N. Fonjungo.


American Journal of Clinical Pathology | 2009

Critical role of developing national strategic plans as a guide to strengthen laboratory health systems in resource-poor settings.

John N. Nkengasong; Tsehaynesh Mesele; Sherry Orloff; Yenew Kebede; Peter N. Fonjungo; Ralph Timperi; Deborah L. Birx

Medical laboratory services are an essential, yet often neglected, component of health systems in developing countries. Their central role in public health, disease control and surveillance, and patient management is often poorly recognized by governments and donors. However, medical laboratory services in developing countries can be strengthened by leveraging funding from other sources of HIV/AIDS prevention, care, surveillance, and treatment programs. Strengthening these services will require coordinated efforts by national governments and partners and can be achieved by establishing and implementing national laboratory strategic plans and policies that integrate laboratory systems to combat major infectious diseases. These plans should take into account policy, legal, and regulatory frameworks; the administrative and technical management structure of the laboratories; human resources and retention strategies; laboratory quality management systems; monitoring and evaluation systems; procurement and maintenance of equipment; and laboratory infrastructure enhancement. Several countries have developed or are in the process of developing their laboratory plans, and others, such as Ethiopia, have implemented and evaluated their plan.


AIDS Research and Human Retroviruses | 2000

Presence of diverse human immunodeficiency virus type 1 viral variants in Cameroon.

Peter N. Fonjungo; Eitel Mpoudi; Judith N. Torimiro; George Alemnji; Laura T. Eno; John N. Nkengasong; Feng Gao; Mark Rayfield; Thomas M. Folks; Danuta Pieniazek; Renu B. Lal

Phylogenetic analysis of the gp41 region of 123 HIV-1-seropositive specimens from Cameroon showed that 89 were subtype A (71% of these sequences were IbNg-like), 12 (10%) were subtype D, 11 (9%) were subtype G, 5 (4%; closely related to subtype F2) were subtype F, 1 was subtype H, 2 (1.6%) remained unclassifiable, while 3 were group O. Further analysis of the two unclassifiable specimens in gag(p24), pol(prot), and env (C2V3 or gp41) showed that one (98CM19) was a complex mosaic between subtype A in p24 and subtype J prot, and unclassifiable in env (C2V3 or gp41). The second, 98CM63, clustered distinctly from all known subtypes in p24, prot, C2V3, or gp41. 98CM63 clustered with a specimen from Cyprus and these two geographically and epidemiologically unlinked specimens, with their distinct clustering pattern, may represent a new subcluster of subtype A. In conclusion, these findings confirm the high HIV-1 genetic variability and further suggest the continuous appearance of new viral strains in this population.


Journal of Clinical Microbiology | 2002

Human Immunodeficiency Virus Type 1 Group M Protease in Cameroon: Genetic Diversity and Protease Inhibitor Mutational Features

Peter N. Fonjungo; Eitel Mpoudi; Judith N. Torimiro; George Alemnji; Laura T. Eno; Esther J. Lyonga; John N. Nkengasong; Renu B. Lal; Mark Rayfield; Marcia L. Kalish; Thomas M. Folks; Danuta Pieniazek

ABSTRACT To establish a baseline for monitoring resistance to protease inhibitors (PIs) and examining the efficacy of their use among persons in Cameroon infected with human immunodeficiency virus type 1 (HIV-1), we analyzed genetic variability and PI resistance-associated substitutions in PCR-amplified protease (PR) sequences in strains isolated from 110 HIV-1-infected, drug-naïve Cameroonians. Of the 110 strains, 85 were classified into six HIV-1 PR subtypes, A (n = 1), B (n = 1), F (n = 4), G (n = 7), H (n = 1), and J (n = 7), and a circulating recombinant form, CRF02-AG (n = 64). PR genes from the remaining 25 (23%) specimens were unclassifiable, whereas 2% (7 of 301) unclassifiable PR sequences were reported for a global collection. Two major PI resistance-associated mutations, 20M and 24I, were detected in strains from only two specimens, whereas secondary mutations were found in strains from all samples except one strain of subtype B and two strains of CRF02-AG. The secondary mutations showed the typical PI resistance-associated pattern for non-subtype B viruses in both classifiable and unclassifiable PR genes, with 36I being the predominant (99%) mutation, followed by 63P (18%), 20R (15%), 77I (13%), and 10I or 10V (11%). Of these mutations, dual and triple PI resistance-associated substitutions were found in 38% of all the Cameroonian strains. Compared with classifiable PR sequences, unclassifiable sequences had significantly more dual and triple substitutions (64% versus 30%; P = 0.004). Phenotypic and clinical evaluations are needed to estimate whether PI resistance during antiretroviral drug treatment occurs more rapidly in individuals infected with HIV-1 strains harboring multiple PI resistance-associated substitutions. This information may be important for determination of appropriate drug therapies for HIV-1-infected persons in Cameroon, where more than one-third of HIV-1 strains were found to carry dual and triple minor PI resistance-associated mutations.


Emerging Infectious Diseases | 2005

Central African Hunters Exposed to Simian Immunodeficiency Virus

Marcia L. Kalish; Nathan D. Wolfe; Clement B. Ndongmo; Janet M. McNicholl; Kenneth E. Robbins; Michael Aidoo; Peter N. Fonjungo; George Alemnji; Clement Zeh; Cyrille F. Djoko; Eitel Mpoudi-Ngole; Donald S. Burke; Thomas M. Folks

HIV-seronegative Cameroonians with exposure to nonhuman primates were tested for simian immunodeficiency virus (SIV) infection. Seroreactivity was correlated with exposure risk (p<0.001). One person had strong humoral and weak cellular immune reactivity to SIVcol peptides. Humans are exposed to and possibly infected with SIV, which has major public health implications.


Tropical Medicine & International Health | 2014

Strengthening national health laboratories in sub-Saharan Africa: a decade of remarkable progress

George Alemnji; Clement Zeh; Katy Yao; Peter N. Fonjungo

Efforts to combat the HIV/AIDS pandemic have underscored the fragile and neglected nature of some national health laboratories in Africa. In response, national and international partners and various governments have worked collaboratively over the last several years to build sustainable laboratory capacities within the continent. Key accomplishments reflecting this successful partnership include the establishment of the African‐based World Health Organization Regional Office for Africa (WHO‐AFRO) Stepwise Laboratory Quality Improvement Process Towards Accreditation (SLIPTA); development of the Strengthening Laboratory Management Toward Accreditation (SLMTA) training programme; and launching of a Pan African‐based institution, the African Society for Laboratory Medicine (ASLM). These platforms continue to serve as the foundations for national health laboratory infrastructure enhancement, capacity development and overall quality system improvement. Further targeted interventions should encourage countries to aim at integrated tiered referral networks, promote quality system improvement and accreditation, develop laboratory policies and strategic plans, enhance training and laboratory workforce development and a retention strategy, create career paths for laboratory professionals and establish public–private partnerships. Maintaining the gains and ensuring sustainability will require concerted action by all stakeholders with strong leadership and funding from African governments and from the African Union.


Journal of Public Health Policy | 2012

Laboratory equipment maintenance: a critical bottleneck for strengthening health systems in sub-Saharan Africa?

Peter N. Fonjungo; Yenew Kebede; Tsehaynesh Messele; Gonfa Ayana; Gudeta Tibesso; Almaz Abebe; John N. Nkengasong; Thomas A. Kenyon

Properly functioning laboratory equipment is a critical component for strengthening health systems in developing countries. The laboratory can be an entry point to improve population health and care of individuals for targeted diseases – prevention, care, and treatment of TB, HIV/AIDS, and malaria, plus maternal and neonatal health – as well as those lacking specific attention and funding. We review the benefits and persistent challenges associated with sustaining laboratory equipment maintenance. We propose equipment management policies as well as a comprehensive equipment maintenance strategy that would involve equipment manufacturers and strengthen local capacity through pre-service training of biomedical engineers. Strong country leadership and commitment are needed to assure development and sustained implementation of policies and strategies for standardization of equipment, and regulation of its procurement, donation, disposal, and replacement.


Aids Patient Care and Stds | 2014

The Centrality of Laboratory Services in the HIV Treatment and Prevention Cascade: The Need for Effective Linkages and Referrals in Resource-Limited Settings

George Alemnji; Peter N. Fonjungo; Barbara Van Der Pol; Trevor Peter; Rami Kantor; John N. Nkengasong

Strong laboratory services and systems are critical for delivering timely and quality health services that are vital to reduce patient attrition in the HIV treatment and prevention cascade. However, challenges exist in ensuring effective laboratory health systems strengthening and linkages. In particular, linkages and referrals between laboratory testing and other services need to be considered in the context of an integrated health system that includes prevention, treatment, and strategic information. Key components of laboratory health systems that are essential for effective linkages include an adequate workforce, appropriate point-of-care (POC) technology, available financing, supply chain management systems, and quality systems improvement, including accreditation. In this review, we highlight weaknesses of and gaps between laboratory testing and other program services. We propose a model for strengthening these systems to ensure effective linkages of laboratory services for improved access and retention in care of HIV/AIDS patients, particularly in low- and middle-income countries.


Journal of Clinical Virology | 2012

Evaluation of blood collection filter papers for HIV-1 DNA PCR

Silvina Masciotra; Samoel Khamadi; Ebi Celestin Bile; Adrian Puren; Peter N. Fonjungo; Shon Nguyen; Mulu Girma; Robert Downing; Artur Ramos; Shambavi Subbarao; Dennis Ellenberger

BACKGROUND The collection of dried blood spots (DBS) on Whatman 903 cards has facilitated for years the detection of HIV-1 in infants by DNA PCR as early as 4-6 weeks after birth in resource-limited settings (RLS), but alternate blood collection devices are proving to be necessary. OBJECTIVES The qualitative detection of HIV-1 DNA by PCR from DBS prepared on three commercially available blood collection cards was evaluated at the Centers for Disease Control and Prevention (CDC) and in four laboratories in Africa. STUDY DESIGN DBS were prepared on Ahlstrom grade 226, Munktell TFN and Whatman 903, and stored under a variety of conditions. DBS were stored at ambient temperature (RT), 37°C with high humidity, and -20°C for varying lengths of time. The presence of HIV-1 DNA was tested using Roche Amplicor HIV-1 DNA (v 1.5) weekly for 4 weeks and at weeks 8 and 12 (RT and 37°C), at weeks 4, 8, and 18 (-20°C) of storage. DBS specimens were also tested after international shipment at RT. In addition, after nearly 3 years storage at -20°C, DBS were also evaluated independently using the COBAS Ampliprep/TaqMan HIV-1 Qual and Abbott RealTime HIV-1 Qualitative tests. RESULTS HIV-1 DNA was detected equally well on the three blood collection cards regardless of storage conditions and PCR assay. CONCLUSIONS Ahlstrom 226 and Munktell TFN papers were comparable to Whatman 903 for HIV-1 DNA detection and may be considered as optional blood collection devices in resource-limited countries.


The Journal of Infectious Diseases | 2016

Improved Specimen-Referral System and Increased Access to Quality Laboratory Services in Ethiopia: The Role of the Public-Private Partnership

Yenew Kebede; Peter N. Fonjungo; Gudeta Tibesso; Ritu Shrivastava; John N. Nkengasong; Thomas A. Kenyon; Amha Kebede; Renuka Gadde; Gonfa Ayana

BACKGROUND Nonstandardized specimen-transport logistics, lack of laboratory personnel to transport specimens, lack of standard specimen containers, and long turnaround time (TAT) hindered access to quality laboratory services. The objective of the Becton, Dickinson, and Company (BD)-US Presidents Emergency Plan for AIDS Relief (PEPFAR) Public-Private Partnership (PPP) was to support country-specific programs to develop integrated laboratory systems, services, and quality improvement strategies, with an emphasis on strengthening the specimen-referral system (SRS). METHODS In 2007, through the Centers for Disease Control and Prevention (CDC), the Ethiopian Public Health Institute (EPHI) joined with the BD-PEPFAR PPP to strengthen laboratory systems. A joint planning and assessment committee identified gaps in the SRS for prioritization and intervention and piloted the system in Addis Ababa and Amhara Region. RESULTS The PPP established standardized, streamlined specimen logistics, using the Ethiopian Postal Service Enterprise to support a laboratory network in which 554 facilities referred specimens to 160 laboratories. The PPP supported procuring 400 standard specimen containers and the training of 586 laboratory personnel and 81 postal workers. The average TAT was reduced from 7 days (range, 2-14 days) to 2 days (range, 1-3 days) in Addis Ababa and from 10 days (range, 6-21 days) to 5 days (range, 2-6 days) in Amhara Region. CONCLUSIONS This study highlights the feasibility and untapped potential of PPPs to strengthen laboratory systems. This planned and structured approach to improving specimen referral enhanced access to quality laboratory services.


AIDS | 2016

Ensuring quality: a key consideration in scaling-up HIV-related point-of-care testing programs

Peter N. Fonjungo; Saladin Osmanov; Joel Kuritsky; Jean Bosco Ndihokubwayo; Pam Bachanas; Rosanna W. Peeling; Ralph Timperi; Glenn Fine; Wendy Stevens; Vincent Habiyambere; John N. Nkengasong

Objective:The objective of the WHO/US Presidents Emergency Plan for AIDS Relief consultation was to discuss innovative strategies, offer guidance, and develop a comprehensive policy framework for implementing quality-assured HIV-related point-of-care testing (POCT). Methods:The consultation was attended by representatives from international agencies (WHO, UNICEF, UNITAID, Clinton Health Access Initiative), United States Agency for International Development, Centers for Disease Control and Prevention/Presidents Emergency Plan for AIDS Relief Cooperative Agreement Partners, and experts from more than 25 countries, including policy makers, clinicians, laboratory experts, and program implementers. Main outcomes:There was strong consensus among all participants that ensuring access to quality of POCT represents one of the key challenges for the success of HIV prevention, treatment, and care programs. The following four strategies were recommended: implement a newly proposed concept of a sustainable quality assurance cycle that includes careful planning; definition of goals and targets; timely implementation; continuous monitoring; improvements and adjustments, where necessary; and a detailed evaluation; the importance of supporting a cadre of workers [e.g. volunteer quality corps (Q-Corps)] with the role to ensure that the quality assurance cycle is followed and sustained; implementation of the new strategy should be seen as a step-wise process, supported by development of appropriate policies and tools; and joint partnership under the leadership of the ministries of health to ensure sustainability of implementing novel approaches. Conclusion:The outcomes of this consultation have been well received by program implementers in the field. The recommendations also laid the groundwork for developing key policy and quality documents for the implementation of HIV-related POCT.

Collaboration


Dive into the Peter N. Fonjungo's collaboration.

Top Co-Authors

Avatar

John N. Nkengasong

Centers for Disease Control and Prevention

View shared research outputs
Top Co-Authors

Avatar

George Alemnji

Centers for Disease Control and Prevention

View shared research outputs
Top Co-Authors

Avatar

Danuta Pieniazek

Centers for Disease Control and Prevention

View shared research outputs
Top Co-Authors

Avatar

Yenew Kebede

Centers for Disease Control and Prevention

View shared research outputs
Top Co-Authors

Avatar

Thomas M. Folks

Centers for Disease Control and Prevention

View shared research outputs
Top Co-Authors

Avatar

Clement Zeh

Centers for Disease Control and Prevention

View shared research outputs
Top Co-Authors

Avatar

Eitel Mpoudi

Centers for Disease Control and Prevention

View shared research outputs
Top Co-Authors

Avatar

Laura T. Eno

Centers for Disease Control and Prevention

View shared research outputs
Top Co-Authors

Avatar

Marcia L. Kalish

Centers for Disease Control and Prevention

View shared research outputs
Top Co-Authors

Avatar

Mark Rayfield

Centers for Disease Control and Prevention

View shared research outputs
Researchain Logo
Decentralizing Knowledge